Pharmaceutical

Coeptis licenses Deverra Therapeutics’ clinical stage assets

Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.

Aug 18, 2023 - 20:00
Coeptis licenses Deverra Therapeutics’ clinical stage assets
Coeptis Therapeutics has exclusively licensed allogeneic immuno-oncology platform and clinical stage assets from Deverra Therapeutics.
Read the original article

Tags:

Previous Article

Signal: Abortion pill restriction may drive more patients to off-label drug

Next Article

Bruker to buy cell biology company PhenomeX for $108m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

FDA launches new rare disease innovation hub

FDA launches new rare disease innovation hub

Jul 20, 2024

Searchlight licenses Mithra’s menopause drug Donesta for Canadian market

Searchlight licenses Mithra’s menopause drug Donesta fo...

Jul 31, 2023

STAT+: Chamber of Commerce tries new legal arguments to challenge Medicare drug-price negotiation

STAT+: Chamber of Commerce tries new legal arguments to...

Jun 10, 2023